Multiple sclerosis (MS) is characterized by inflammation, demyelination and lesions in the central nervous system (CNS) that results in the physical and cognitive disabilities in patients. Immune cells get access into the brain region, after infection in the blood brain barrier (BBB) due to bacteria/virus or by genetic predisposition, where the autoimmune response may induce the demyelination, inflammation as well as neurodegeneration in brain areas. Various types of therapeutics are used worldwide approved by the food and drug administration (FDA) for the management of MS. Hence, side effects of conventional therapy goes hand in hand. The advancement in nanomedicines have opened window for the management of various disorders of neurodegeneration including MS. Various clinical trials are in process to explore the etiology of MS and in this connection animal models like experimental autoimmune encephalomyelitis (EAE) have promising outcomes for the management of MS by using nanomedicines that give new insights. The current review elaborates the scope of nanomedicines with respect to MS patients.